Stocks Higher as In...
Health Care: Drugs
Achillion Pharmaceuticals Inc. (ACHN: NASDAQ)
$8.13 0.12 | 1.50%
06/19/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 2.61M | 247.00K | 2.44M | -294.00K |
| Cost of Sales | 0.00 | 0.00 | -940.00K | -1.11M |
| Gross Operating Profit | 2.61M | 247.00K | 3.38M | 818.00K |
| Selling, General, and Administrative Expenses | 10.90M | 9.15M | 7.20M | 6.55M |
| Research & Development | 39.00M | 35.44M | 20.53M | 18.42M |
| Operating Income before D & A (EBITDA) | -47.29M | -44.35M | -24.36M | -24.15M |
| Depreciation & Amortization | 852.00K | 805.00K | 940.00K | 1.11M |
| Interest Income | 234.00K | 186.00K | 101.00K | 172.00K |
| Other Income - Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -47.91M | -44.97M | -25.20M | -25.37M |
| Interest Expense | 68.00K | 45.00K | 284.00K | 564.00K |
| Pre-Tax Income | -47.98M | -45.01M | -25.48M | -25.93M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -47.13M | -44.21M | -25.48M | -25.93M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -47.13M | -44.21M | -25.48M | -25.93M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -47.13M | -44.21M | -25.48M | -25.93M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-47.13M | -44.21M | -25.48M | -25.66M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -47.13M | -44.21M | -25.48M | -25.93M |
| Basic EPS from Continuing Ops. | -0.64 | -0.69 | -0.57 | -0.98 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.64 | -0.69 | -0.57 | -0.98 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.64 | -0.69 | -0.57 | -0.98 |
| Basic Normalized Net Income/Share | -0.64 | -0.69 | -0.57 | -0.97 |
| EPS fr Continuing Ops. | -0.64 | -0.69 | -0.57 | -0.98 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.64 | -0.69 | -0.57 | -0.98 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.64 | -0.69 | -0.57 | -0.98 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.64 | -0.69 | -0.57 | -0.97 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ACHN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- UserMy Watch List
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Rising On Unusual Vo...
- UserThe cash burners
- ContributorStocks Under-$10 Moving Hig...
Latest ACHN Headlines from TheStreet
- 5 Stocks Seeing Bullish Options Activity 06.13.13 | 12:06 pm
- Achillion To Present At The Wells Fargo 2013 Healthcare Conference 06.12.13 | 06:06 am
- Biotech Stock Mailbag: 2013 Clinical Trials Calendar 06.07.13 | 07:06 am
- Achillion Pharmaceuticals (ACHN) Shares Cross Above 200 DMA 05.31.13 | 04:05 pm
- Achillion Nominates ACH-3422 As Nucleotide For The Treatment Of Chronic HCV 05.30.13 | 06:05 am
- Achillion Names Milind Deshpande, Ph.D., As President, Chief Executive Officer, Following Announced Retirement Of Michael Kishbauch 05.28.13 | 04:05 pm
- Achillion Appoints Dr. David Apelian As Chief Medical Officer And Expands Clinical Operations Team 05.15.13 | 06:05 am
- Achillion To Present At Three Upcoming Investor Conferences 05.09.13 | 06:05 am
- Achillion Reports First Quarter 2013 Financial Results 05.07.13 | 06:05 am
- Oversold Conditions For Achillion Pharmaceuticals 05.02.13 | 12:05 pm
Press Releases for ACHN
- Emerald Holds Annual Groundhog Day Investment Forum - Business Wire 02.06.12 | 08:02 am
Partner Headlines for ACHN
- Gilead Stock Hits New High As HCV Drug Keeps Rocking - Investor's Business Daily 02.19.13 | 04:02 pm
- New Second Generation Combination Therapy For HCV - First Or Best In The Market - Part 3 - Seeking Alpha 11.30.12 | 08:11 am
- Cramer's Mad Money - 8 Things To Watch In The Week Ahead (9/28/12) - Seeking Alpha 09.30.12 | 07:09 am
- Achillion Pharma draws bullish bet - NASDAQ 09.25.12 | 04:09 pm
- 3 Stocks Upgraded On September 19 To Consider - Seeking Alpha 09.21.12 | 10:09 am
- Morning Market Movers - Benzinga 09.19.12 | 09:09 am
- REVEALED: New Analyst Stock Coverage to Assess Today - Wall St. Cheat Sheet 06.13.12 | 04:06 am
- Stock Insights: Achillion Pharmaceuticals, DG FastChannel, Tempur Pedic, Iron Mountain, Nasdaq OMX June 7th - Wall St. Cheat Sheet 06.07.12 | 10:06 am
- Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C - Benzinga 04.21.12 | 04:04 pm
- UPDATE: Bank of America Raises Actuant's PT - Benzinga 03.08.12 | 01:03 pm
